Full history for every metric is available with a Kvantra account
Mind Cure Health Inc. (MCUR.CN)
Key financial summary
Financials in CAD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | - | - | - | - | 0 | 0 | 0 |
| Operating profit | CAD m | -6 | -4 | |||||
| Net profit | CAD m | - | - | - | - | -10 | -22 | - |
| EPS reported | CAD | -0.24 | - | |||||
| Operating cashflow per share | CAD | -0.10 | -0.10 | |||||
| Capex per share | CAD | 0.01 | 0.01 | |||||
| FCF per share | CAD | -0.10 | -0.10 | |||||
| Free cash flow | CAD m | -10 | -6 | |||||
| Net debt | CAD m | -9 | -1 | |||||
| Book value equity | CAD m | 7 | 16 | |||||
| Book value per share | CAD | 0.08 | 0.17 | |||||
| Number of shares | m | 93.85 | 93.91 | |||||
| DPS (TTM paid) | CAD | 0.00 | 0.00 |
Financial summary
Financials in CAD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.93 | 0.45 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.67 | -1.09 | |||||
| EV/EBITDA LTM | x | 0.15 | -1.68 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -339.44% | -316.81% | |||||
| FCF Yield | % | -149.66% | -92.03% | |||||
| Quality | ||||||||
| ROE | % | -314.02% | -160.99% | |||||
| ROIC | % | -82.99% | -82.99% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | -30.29 | |||||
| Net Debt/EBITDA | x | 0.62 | 0.62 | |||||
| EBIT/Net interest | x | -67.21 | -67.21 | |||||
| Net debt/market cap | % | -132.59% | -19.62% | |||||
| Net debt/Equity | x | -1.23 | -0.09 | |||||
| Gross debt/equity | x | 0.00 | 0.01 | |||||
Company overview
Mind Cure Health Inc. operates as a life sciences firm, dedicated to creating and marketing mental health and wellness solutions across North America. The company's strategy revolves around advancing digital therapeutic technologies and exploring psychedelic compounds, with the goal of rapidly expanding access to scientifically validated, evidence-based mental health treatments. Among its key innovations is iSTRYM, a unique digital therapeutic software application designed to enhance the entire healing journey for patients and clinicians throughout all phases of therapy. It also offers PsyCollage, a bioinformatics platform crucial for guiding research by identifying priority programs. Furthermore, Mind Cure Health produces synthetic ibogaine for distribution to researchers and clinicians, and investigates various psychedelic compounds, particularly ibogaine, for its potential in treating traumatic brain injuries and related conditions. Established in 2020, Mind Cure Health Inc. maintains its headquarters in Vancouver, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Mind Cure Health Inc. (MCUR.CN)
Mind Cure Health Inc. operates as a life sciences firm, dedicated to creating and marketing mental health and wellness solutions across North America. The company's strategy revolves around advancing digital therapeutic technologies and exploring psychedelic compounds, with the goal of rapidly expanding access to scientifically validated, evidence-based mental health treatments. Among its key innovations is iSTRYM, a unique digital therapeutic software application designed to enhance the entire healing journey for patients and clinicians throughout all phases of therapy. It also offers PsyCollage, a bioinformatics platform crucial for guiding research by identifying priority programs. Furthermore, Mind Cure Health produces synthetic ibogaine for distribution to researchers and clinicians, and investigates various psychedelic compounds, particularly ibogaine, for its potential in treating traumatic brain injuries and related conditions. Established in 2020, Mind Cure Health Inc. maintains its headquarters in Vancouver, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free